Sex differences in heart failure with preserved ejection fraction
10.1161/jaha.120.018574 · doi-reference
Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute
10.1161/circulationaha.108.815944 · doi-reference
The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial
10.1016/s0735-1097(01)01608-4 · doi-reference
The role of sodium-hydrogen ion exchange in patients undergoing coronary artery bypass grafting
10.1046/j.1540-8191.18.s1.4.x · doi-reference
Inhibition of the Na+-H+ exchanger with cariporide abolishes stretch-induced calcium but not sodium accumulation in mouse ventricular myocytes
10.1016/j.ceca.2004.06.006 · doi-reference
Na+/H+ exchangers of mammalian cells
10.1074/jbc.272.36.22373 · doi-reference
Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients
10.3389/fphys.2018.01575 · doi-reference
Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy
10.3389/fendo.2022.1011669 · doi-reference
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
10.1093/cvr/cvaa123 · doi-reference
Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway
10.1016/j.redox.2022.102288 · doi-reference
Empagliflozin improves diastolic function in HFpEF by restabilizing the mitochondrial respiratory chain
10.1161/circheartfailure.123.011107 · doi-reference
Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
10.1016/j.molmet.2022.101620 · doi-reference
Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial
10.1161/circulationaha.123.065134 · doi-reference
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
10.1038/s41591-021-01536-x · doi-reference
Identification of a Mg2+-sensitive ORF in the 5'-leader of TRPM7 magnesium channel mRNA
10.1093/nar/gku951 · doi-reference
Intracellular pH modulates cytosolic free magnesium in cultured chicken heart cells
10.1152/ajpcell.1992.262.4.c1024 · doi-reference
Activation of the Na(+)-H+ exchanger modulates angiotensin II-stimulated Na(+)-dependent Mg2+ transport in vascular smooth muscle cells in genetic hypertension
10.1161/01.hyp.34.3.442 · doi-reference
Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: a post hoc analysis of 10 randomized, placebo-controlled trials
10.1016/j.jdiacomp.2019.06.007 · doi-reference
Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?
10.1007/s10741-022-10220-2 · doi-reference
Inhibition of the sodium-proton antiporter (exchanger) is a plausible mechanism of potential benefit and harm for drugs designed to block sodium glucose co-transporter 2
10.31083/j.rcm.2018.02.021 · doi-reference
Dapagliflozin in patients with heart failure and reduced ejection fraction
10.1056/nejmoa1911303 · doi-reference
Suppression of TRPM7 enhances TRAIL-induced apoptosis in triple-negative breast cancer cells
10.1002/jcp.29820 · doi-reference
Identification of TG100-115 as a new and potent TRPM7 kinase inhibitor, which suppresses breast cancer cell migration and invasion
10.1016/j.bbagen.2017.01.034 · doi-reference
Crucial role for sensory nerves and Na/H exchanger inhibition in dapagliflozin- and empagliflozin-induced arterial relaxation
10.1093/cvr/cvae156 · doi-reference
Crosstalk between sodium-glucose cotransporter inhibitors and sodium-hydrogen exchanger 1 and 3 in cardiometabolic diseases
10.3390/ijms222312677 · doi-reference
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
10.1016/j.phrs.2020.104781 · doi-reference
Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts
10.1093/cvr/cvz004 · doi-reference
Dapagliflozin attenuates Na(+)/H(+) Exchanger-1 in cardiofibroblasts via AMPK activation
10.1007/s10557-018-6837-3 · doi-reference
Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits
10.1007/s00125-016-4134-x · doi-reference
Human fetal ventricular cardiomyocyte, RL-14 cell line, is a promising model to study drug metabolizing enzymes and their associated arachidonic acid metabolites
10.1016/j.vascn.2014.11.005 · doi-reference
Publisher correction: blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly
10.1038/s41590-020-0686-5 · doi-reference
Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction
10.1038/s41590-018-0272-2 · doi-reference
TRPM7 kinase mediates hypomagnesemia-induced seizure-related death
10.1038/s41598-023-34789-2 · doi-reference
Role of mitochondrial oxidative stress in glucose tolerance, insulin resistance, and cardiac diastolic dysfunction
10.1161/jaha.115.003046 · doi-reference
Circulating S-glutathionylated cMyBP-C as a biomarker for cardiac diastolic dysfunction
10.1161/jaha.122.025295 · doi-reference
Mitochondrial dysfunction causing cardiac sodium channel downregulation in cardiomyopathy
10.1016/j.yjmcc.2012.10.011 · doi-reference
Rosmarinic acid, as an NHE1 activator, decreases skin surface pH and improves the skin barrier function
10.3390/ijms23073910 · doi-reference
Cariporide (HOE642), a selective Na+-H+ exchange inhibitor, inhibits the mitochondrial death pathway
10.1161/01.cir.0000093277.20968.c7 · doi-reference
Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells
10.1371/journal.pone.0247234 · doi-reference
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice
10.1016/j.metabol.2020.154324 · doi-reference
